BUFFALO, N.Y. – Few benefits and many risks will result from the marketing of Zohydro, the extended-release formulation of hydrocodone, according to Richard D. Blondell, MD, vice chair for addiction medicine at the University at Buffalo and professor of family medicine in the UB School of Medicine and Biomedical Sciences.